Vestris PG, Gourtaud G, Senechal C, et al. - Based on findings from this study, hormonotherapy (abiraterone or enzalutamide) use is suggested with a tendency for abiraterone in first line for men with African ancestry having metastatic prostate cancer at the castration-resistant stage (mCRPC).

• Use of docetaxel, abiraterone, or enzalutamide has proven beneficial for treating mCRPC in Caucasian population in several studies, however, no strong data exist for men of African ancestry.

• In this monocentric retrospective study, 180 men with mCRPC were analyzed to estimate the overall as well as progression-free survival according to these treatments at the mCRPC stage.

• Median follow-up of 20.7 months showed overall survival did not differ, irrespective of treatment used in the first line.

• Better progression-free survival was achieved with hormonotherapy (abiraterone or enzalutamide) vs with docetaxel, with a particular interest for abiraterone hazard ratio = 0.51.

• Significant link of World Health Organization status and of metastases at diagnosis with the progression was evident.